Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.


Gomez Rivas, Juan ORCID: 0000-0002-0556-3035, Nicoletti, Rossella, Ibáñez, Laura ORCID: 0000-0002-2278-3275, Steinbeisser, Carl ORCID: 0000-0003-1493-3277, de Meulder, Bertrand ORCID: 0000-0002-2108-7657, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip ORCID: 0000-0002-7146-9258 et al (show 11 more authors) (2023) Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program. International journal of surgery protocols, 27 (3). pp. 122-129.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called "triplets", have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission.

Item Type: Article
Uncontrolled Keywords: PIONEER, androgen deprivation therapy, big data, chemotherapy, metastasis, new androgen receptor-targeted agents, predictive model, prostate cancer
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences > School of Medicine
Depositing User: Symplectic Admin
Date Deposited: 02 Feb 2024 11:40
Last Modified: 02 Feb 2024 11:40
DOI: 10.1097/sp9.0000000000000009
Open Access URL: http://10.0.4.73/SP9.0000000000000009
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3178335
Dimensions
Altmetric
CORE (COnnecting REpositories)